Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis

NCT05650060 · clinicaltrials.gov ↗

COMPLETED

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis

Interventions

DRUG: Secukinumab

Sponsor

Novartis Pharmaceuticals